Home › Non-Hodgkinlymfoom › Washington › Seattle
Non-Hodgkinlymfoom klinische studies in Seattle, WA
16 studies voor Non-Hodgkinlymfoom zoeken deelnemers op locaties in en rond Seattle (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruterenFase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekruterenFase 2
- Swedish Cancer Institute, Seattle
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruterenFase 1
- Swedish Cancer Institute (SCI), Seattle
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekruterenFase 1
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RekruterenFase 1/2
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RekruterenFase 1
- Fred Hutch Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RekruterenFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
DALY II USA/ MB-CART2019.1 for DLBCL
RekruterenFase 2
- Fred Hutchinson Cancer Center, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruterenObservatieonderzoek
- Fred Hutchinson Cancer Research Center, Seattle
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RekruterenFase 1/2
- University of Washington Medical Center, Seattle
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruterenObservatieonderzoek
- Kaiser Permanente Washington, Seattle
- Swedish Medical Center-First Hill, Seattle
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RekruterenFase 4
- Swedish Cancer Institute, Seattle
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RekruterenFase 4
- Swedish Cancer Institute, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
RekruterenFase 1
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruterenObservatieonderzoek
- Massive Bio SYNERGY-AI site, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
RekruterenFase 1
- Swedish Cancer Institute, Seattle
Non-Hodgkinlymfoom studies in andere steden
- New York City, NY31 studies
- Houston, TX31 studies
- Boston, MA26 studies
- Nashville, TN21 studies
- Philadelphia, PA20 studies
- Baldwin Park, CA19 studies
- Washington, DC18 studies
- Chicago, IL18 studies
- Atlanta, GA18 studies
- Milwaukee, WI18 studies
- Columbus, OH18 studies
- Dallas, TX17 studies
Andere studies in Seattle
- Niet-kleincellige longkanker53 studies
- Kanker (alle vormen)49 studies
- Prostaatkanker42 studies
- Acute myeloïde leukemie41 studies
- Borstkanker39 studies
- Metastatische kanker39 studies
- Colorectale kanker34 studies
- Longkanker33 studies
- Eierstokkanker30 studies
- Multipel myeloom22 studies
- Blasenkanker21 studies
- Myelodysplastische syndromen21 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.